JW Lifescience

234080 · KOSPI · ₩234080 · JW생명과학

₩10,510▲ ₩70 (0.67%)End-of-day · Oct 28, 2026 · End-of-day prices.
Trade
Alert me

Valuation model · Discounted cash flow (DCF)

We use a 5-year discounted cash flow: the value of the cash the business is expected to produce, in today's money.

Fair value per share

₩38,430

vs the current price (₩10,510)

Enterprise value
₩631B
Equity value
₩609B
WACC
7.0%

Model estimate based on the assumptions shown. Not a price target and not a buy or sell signal. This is not financial advice.

Why the model and the price differ

The model is 266% away from today's price. A gap this size usually means the market expects something the past figures don't show yet, or the model leaves something out. What we can see:

  • To match today's price of ₩10,510, the model needs an operating margin of 5.2% every year (it uses 14.6%).
  • Or revenue growth −27.8 points a year higher than assumed in each of the 5 years.
  • Today's P/E is 5.2× against a typical 8.6× over the last 10 years.

Treat the model as a starting point: change the assumptions to the story you believe, and compare with the multiples check below.

Bear / Base / Bull

Bear
₩23,480
+123.4%
Base
₩38,430
+265.7%
Bull
₩63,876
+507.8%

Bear: revenue growth 3 points lower every year, EBIT margin 2 points lower, WACC 1 point higher. Bull: the opposite.

Assumptions

Sign in to change the assumptions and see the results update. Sign in

Cycle options

Margin path

Every year uses the cycle-average margin (14.6%).

Revenue growth

  • 10.9%

    How much sales grow that year, compared with the year before.

    Default: the last 3 years' revenue growth (10.9% a year, annual reports), fading to 3% by year 5.

  • 8.9%

    How much sales grow that year, compared with the year before.

    Default: the last 3 years' revenue growth (10.9% a year, annual reports), fading to 3% by year 5.

  • 7%

    How much sales grow that year, compared with the year before.

    Default: the last 3 years' revenue growth (10.9% a year, annual reports), fading to 3% by year 5.

  • 5%

    How much sales grow that year, compared with the year before.

    Default: the last 3 years' revenue growth (10.9% a year, annual reports), fading to 3% by year 5.

  • 3%

    How much sales grow that year, compared with the year before.

    Default: the last 3 years' revenue growth (10.9% a year, annual reports), fading to 3% by year 5.

Business

  • 14.6%

    Operating profit as a share of revenue.

    Default: through-the-cycle average of the last 12 months and the last 5 annual reports' operating margins.

  • 27.5%

    Share of operating profit paid as corporate tax.

    Default: Korea's top corporate tax rate (25%) plus 10% local income tax.

  • 3.7%

    The non-cash cost of wearing out equipment, added back to cash flow (% of revenue).

    Default: not in the statements, so 80% of capital spending (most spending replaces equipment that wears out).

  • 4.6%

    Money spent on factories, equipment, software and other long-term assets (% of revenue).

    Default: average of the last 3 annual reports (cash flow statements; equipment and intangibles).

  • 12.3%

    Stock and unpaid customer bills, less unpaid supplier bills, as a % of revenue. Each year's extra revenue ties up this much more cash.

    Default: working capital (current assets less cash and deposits, minus current liabilities other than borrowings) as a share of revenue, averaged over the last 3 years.

Discount rate

  • 2%

    How fast cash flows keep growing every year after year 5.

    Default: about Korea's long-run inflation plus real growth.

  • 4.11%

    Yield on Korea's 10-year government bond: the return with almost no risk.

    Default: Korea Treasury Bond 10-year yield on 2026-10-28.

  • 0.6

    How much the share moves when the market moves: 1 means just like the market.

    Default: 105 weeks of weekly returns against KOSPI (official index); raw beta 0.07, adjusted toward 1 and kept between 0.6 and 2.0.

  • 5.5%

    The extra return investors want for owning shares instead of bonds.

    Default: a typical premium for Korean shares.

  • 5.61%

    The interest rate the company would pay to borrow.

    Default: the 10-year yield plus a 1.5% credit spread.

Starting point

Revenue (TTM to H1 2026)
₩254B
Net debt (borrowings and leases − cash and deposits)
₩23B
+ Stakes and investments
₩590M
Associates, long-term financial assets and deposits (book value)
Shares
15,834,554
Share price
₩10,510
Market cap
₩166B

TTM = trailing 12 months: the last four reported quarters added together. "TTM to H1 2026" is the 12 months up to the latest quarterly or half-year report (H1 = to the end of June). Year 1 grows from there.

Past years and projection

Grey columns are reported results from the annual reports (after-tax EBIT at the model's tax rate), so you can check the growth and margin assumptions against the past. Years 1–5 are the model.

FY2023FY2024FY2025Year 1Year 2Year 3Year 4Year 5
Revenue₩207B₩222B₩258B₩281B₩306B₩328B₩344B₩355B
Growth9.5%7.5%15.9%10.9%8.9%7.0%5.0%3.0%
EBIT₩31B₩36B₩33B₩41B₩45B₩48B₩50B₩52B
EBIT margin14.9%16.1%12.9%14.6%14.6%14.6%14.6%14.6%
After-tax EBIT₩22B₩26B₩24B₩30B₩32B₩35B₩36B₩38B
+ Depreciation———₩10B₩11B₩12B₩13B₩13B
− Capital spending₩8.3B₩10B₩13B₩13B₩14B₩15B₩16B₩16B
− Working capital−₩19B−₩5.6B₩26B₩3.4B₩3.1B₩2.6B₩2B₩1.3B
Free cash flow———₩24B₩27B₩29B₩31B₩33B
Discount factor———0.9350.8730.8160.7630.713
Present value———₩22B₩23B₩24B₩24B₩24B

Terminal value ₩722B, worth ₩515B today: 82% of enterprise value. It assumes spending settles at 110% of depreciation once growth slows to the terminal rate.

Cross-check: what the market has paid before

For cyclical businesses, analysts check a DCF against the multiples the stock has traded at through past cycles. Price / book is the usual anchor for them: P/E looks highest at the bottom of a cycle, when earnings are smallest, and lowest at the top. The price each band would give today:

LowTypicalHigh
Price / book (book value ₩14,321 a share)Now 0.73×₩11,8070.82×₩17,4571.22×₩24,3471.70×
Price / earnings (last 12 months: ₩2,029 a share)Now 5.18×₩8,7104.29×₩17,3538.55×₩34,40717.0×
P/E on run-rate earnings (Q2 2026 × 4: ₩2,024 a share)Now 5.19×₩8,6914.29×₩17,3158.55×₩34,33217.0×

Low, typical and high are the 10th percentile, middle and 90th percentile of month-end multiples since 2021, each against the latest report out by then, per share at today's share count; loss years and P/E above 100 are left out. Run-rate earnings are one quarter × 4, not a forecast. Model estimate based on the assumptions shown. Not a price target and not a buy or sell signal.

Sensitivity

Fair value per share as two inputs change; the middle is the current case.

WACC ↓ · Terminal growth →1.0%1.5%2.0%2.5%3.0%
6.0%₩40,288₩44,039₩48,726₩54,751₩62,783
6.5%₩36,353₩39,347₩43,004₩47,574₩53,449
7.0%₩33,077₩35,511₩38,430₩41,996₩46,452
7.5%₩30,308₩32,317₩34,691₩37,537₩41,014
8.0%₩27,937₩29,617₩31,577₩33,891₩36,667

Now (TTM)

Market cap
₩166B
Enterprise value
₩188B
P/E
5.2×
P/B
0.7×
P/S
0.7×
EV/EBITDA
—
Dividend yield
0.0%

Over time (at each year end)

20252024202320222021
Price₩12,850₩10,880₩12,870₩12,150₩13,850
Market cap₩203B₩172B₩204B₩192B₩219B
P/E7.1×3.9×7.2×12.9×18.0×
P/B0.9×0.9×1.3×1.4×1.7×
P/S0.8×0.8×1.0×1.0×1.3×
EV/EBITDA—————
Dividend yield0.0%0.0%———

Versus similar companies

CompanyP/EP/BP/SEV/EBITDADividend yield
JW Lifescience5.2×0.7×0.7×—0.0%
Samsung Biologics32.0×7.6×14.0×—0.0%
Celltrion27.9×2.5×9.0×—0.0%
Alteogen80.5×29.0×61.2×—0.1%
SK biopharmaceuticals14.7×5.8×6.8×—0.0%
Yuhan24.0×2.4×2.5×31.3×0.8%
HLB—15.7×55.6×—0.0%
Similar companies (median)27.9×6.7×11.5×31.3×0.0%

Calculated from end-of-day prices and filed financial statements. Not a recommendation. This is not financial advice.

Also known as: JW Lifescience / JW생명과학 / 234080 / KRX:234080

Source: KRX statistical information